Standard of Care: Chemotherapy and Surgical Options

The treatment for osteosarcoma is highly standardized but physically demanding. It requires a “sandwich” approach: intensive chemotherapy to start, surgery in the middle, and more chemotherapy to finish. This multi-step process typically lasts between 8 to 10 months in total, and is designed to not only destroy the visible tumor but also to target any microscopic cancer cells that may have traveled elsewhere in the body ^[1][2].

Critical First Step: Fertility Preservation

Because osteosarcoma often strikes during adolescence and young adulthood, and the chemotherapy regimen is highly intensive, there is a significant risk to future fertility. Drugs like Cisplatin can cause permanent damage to reproductive organs. It is essential to discuss fertility preservation (such as sperm banking or egg freezing) with a specialist before starting any chemotherapy ^[3].

The MAP Regimen: The Gold Standard

The primary chemotherapy used for osteosarcoma is known as the MAP regimen. Each letter stands for one of three powerful drugs ^[4]:

• M — High-dose Methotrexate: This drug interferes with the cancer cells’ ability to use folate to make DNA.
• A — Adriamycin (Doxorubicin): Also known as “The Red Devil,” this drug damages the DNA of cancer cells to stop them from dividing.
• P — Platinol (Cisplatin): This drug uses platinum to bind to and damage the cancer cells’ DNA.

Neoadjuvant vs. Adjuvant Therapy

• Neoadjuvant Chemotherapy: This is the first phase, given before surgery. Its goals are to shrink the tumor to make surgery easier and to begin killing any “micrometastases” (tiny spots of cancer that don’t show up on scans) ^[1][2].
• Adjuvant Chemotherapy: This phase occurs after surgery. Even if the surgeon removes the entire visible tumor, this phase is critical to ensure that no invisible cancer cells remain ^[1].

Immediate Side Effects

While on the MAP regimen, patients will experience immediate, intense side effects. These typically include profound hair loss (alopecia), severe nausea, mouth sores (mucositis), and extreme immune suppression (requiring careful monitoring for fevers and potentially hospital stays for low blood counts) ^[5][6].

Protecting the Heart: Dexrazoxane

While Doxorubicin is highly effective, it carries a known risk of damaging the heart muscle over time (cardiotoxicity) ^[7]. To combat this, doctors often use a protective drug called Dexrazoxane ^[8].

• Evidence of Safety: Research confirms that dexrazoxane significantly reduces the risk of heart damage without making the chemotherapy less effective or increasing the risk of other cancers ^[8][9].
• Current Guidelines: It is particularly recommended for children and young adults who will receive high total doses of doxorubicin ^[10][11].

Surgical Options: Saving the Limb

Modern surgery focuses on limb-salvage—removing the tumor and the affected bone while keeping the arm or leg.

• Limb-Salvage Surgery (LSS): In this procedure, the bone removed is replaced with a metal implant (endoprosthesis) or a bone graft ^[12]. When done by an expert team, LSS provides survival rates that are equal to or even better than amputation ^[2][13].
• Rotationplasty: For growing children with lower limb tumors, a specialized procedure called rotationplasty may be offered. The affected bone is removed, and the lower leg is rotated 180 degrees and reattached, allowing the ankle to function as a new knee joint. This provides highly functional outcomes for active kids.
• Amputation: If the tumor has grown into major nerves or blood vessels, or if a limb-salvage would result in a limb that doesn’t work well, amputation may be the safer and more functional choice ^[14].
• Physical Therapy: Regardless of the surgery chosen, intense physical therapy and rehabilitation are required for months afterward to regain strength and mobility.

Why “More” Isn’t Always Better: The EURAMOS-1 Trial

A major clinical trial called EURAMOS-1 investigated whether adding extra chemotherapy drugs (Ifosfamide and Etoposide—the MAPIE regimen) would help “poor responders” (patients whose tumors showed less than 90% death after the first phase of chemo) ^[15].

• The Findings: The study found that adding these extra drugs did not improve survival and actually caused significantly more side effects, such as severe infections and lower blood counts ^[15].
• The Outcome: Because of this research, the standard of care remains the original MAP regimen, even for those who do not show a perfect response to the initial treatment ^[16][17].